XORTX Therapeutics Inc. (TSXV:XRTX)
Canada · Delayed Price · Currency is CAD | Market Cap | 3.97M -48.8% |
| Revenue (ttm) | n/a |
| Net Income | -2.71M |
| EPS | -0.69 |
| Shares Out | 6.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,017 |
| Average Volume | 6,928 |
| Open | 0.5700 |
| Previous Close | 0.5800 |
| Day's Range | 0.5700 - 0.5700 |
| 52-Week Range | 0.5200 - 1.9700 |
| Beta | 0.15 |
| RSI | 27.44 |
| Earnings Date | Mar 26, 2026 |
About XORTX Therapeutics
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment... [Read more]
News
Why Align Technology Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Shares of Align Technology Inc (NASDAQ: ALGN) rose sharply in pre-market trading after the company reported better-than-expected fourth-quarter financial results. Align Tech reported quarterly earnin...
XORTX Extends Closing Of Renal Anti-Fibrotic Therapeutic Program Acquisition; Stock Soars
(RTTNews) - XORTX Therapeutics Inc. (XRTX), a late-stage clinical pharmaceutical company that develops therapies for gout and progressing kidney diseases, has entered into an extension agreement with ...
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
CALGARY, Alberta, Oct. 21, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focuse...
XORTX Therapeutics (XRTX) Secures Nasdaq Extension to Meet Bid Price Rule
XORTX Therapeutics (XRTX) Secures Nasdaq Extension to Meet Bid Price Rule
XORTX Therapeutics gains 180-day extension from Nasdaq to regain $1.00 bid price compliance
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focuse...
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focuse...
XORTX (XRTX) Acquires Renal Therapeutic Program from Vectus
XORTX (XRTX) Acquires Renal Therapeutic Program from Vectus
XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
Acquisition includes novel new chemical entity VB4-P5 with potential to address significant unmet needs in rare and large-market kidney diseases Acquisition includes novel new chemical entity VB4-P5 w...
XORTX Therapeutics files to sell up to 4.76M shares
XORTX Therapeutics goes ‘toe to toe’ with gout by accelerating its lead drug program targeting this complex disease
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | FSE: ANU), a late-stage clinical pharmaceutical company, pivoted to prioritize and accelerate its lead gout program in Q1 2025, while continuing to...
XORTX Initiates IND Preparation for XORLO™ in Gout Program
Engagement with Allucent supports NDA pathway and advancement of late-stage gout program Engagement with Allucent supports NDA pathway and advancement of late-stage gout program
XORTX Completes USD $114,500 Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Aug. 08, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”)...
XORTX Completes Non-Brokered Private Placement of Units
Not For Distribution to United States News Wire Services or for Dissemination in the United States CALGARY, Alberta, July 22, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”...
XORTX Announces USD $925,000 Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, June 26, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”...
XORTX Therapeutics looks to raise $3M through private placement
XORTX Therapeutics (XRTX) said it was looking to raise $3M through a non-brokered private placement.
XORTX Announces USD $3 Million Offering
CALGARY, Alberta, May 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused...
XORTX Therapeutics (XRTX) Faces Nasdaq Compliance Challenge
XORTX Therapeutics (XRTX) Faces Nasdaq Compliance Challenge
XORTX Therapeutics receives Nasdaq notice for non-compliance
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
CALGARY, Alberta, April 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focus...
ARMISTICE CAPITAL, LLC Acquires Shares in XORTX Therapeutics Inc
ARMISTICE CAPITAL, LLC Acquires Shares in XORTX Therapeutics Inc
XORTX Announces Change of Auditor
CALGARY, Alberta, Jan. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focuse...
IRW-News: XORTX Therapeutics Inc.: XORTX kündigt Präsentation auf dem Rare and Genetic Disease Summit an
IRW-PRESS: XORTX Therapeutics Inc.: XORTX kündigt Präsentation auf dem Rare and Genetic Disease Summit an
XORTX Announces Presentation at the Rare and Genetic Disease Summit
CALGARY, Alberta, Dec. 12, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focuse...
XORTX Therapeutics files to sell 810,810 common shares for holders
Read about the latest financial filings from XORTX Therapeutics (XRTX) on Seeking Alpha to stay updated on their financial performance and potential growth.